Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06529406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Study acronym: COAST
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 24 to 100 Eligibility criteria expanded, about 15 words · Site contacts updated at 1 of 3 sitesv4 Show 2 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Site contacts updated at 1 of 3 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Secondary endpoints revised (7) Site details revised at 2 of 3 sites · Eligibility criteria shortened, about 2 wordsv3 Show 2 more changesShow less
    • Site details revised at 2 of 3 sites
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Phase: Phase 1/2 to Phase 4 Trial status: Not Yet Recruiting to Recruiting · Enrollment target: 48 to 24 · Study sites: 2 to 3 · 1 morev2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 48 to 24
    • Study sites: 2 to 3
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Trial Details
NCT Number NCT06529406
Lead Sponsor University of Colorado, Denver
Conditions Relapsing Multiple Sclerosis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov